Lung cancer is the leading cause of cancer death worldwide . Exposure to hazards certainly can play a causative role in lung cancer, but many who are exposed to these hazards don’t go on to develop lung cancer and similarly, people who are not exposed to hazards can develop lung cancer.
From a detection and treatment perspective, lung cancer is difficult to detect at an early stage, and the low survival rates in this patient population reflects this late stage detection. Advancements have been made in the biology that drives lung cancer, as well as tools for early detection. These advances, coupled with genomic profiling, and novel biomarkers, have led to the development of new treatments and radiation therapies has the potential to reduce the mortality associated with lung cancer. 
In this program, experts in this space will discuss new biomarkers for lung cancer, and new treatments for the disease that they feel lead to better patient experiences. We will also cover early detection and prevention initiatives and technologies for lung cancer that can be used on patients at high risk of developing the disease, and for correct diagnosis.
 American Lung Cancer Research Foundation
 American Lung Association
 US National Library of Medicine, National Institutes of Health